Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Iovance Biotherapeutics Stock Is Surging: Here's Why

Published 05/12/2022, 14:00
Updated 05/12/2022, 15:10
© Reuters.  Iovance Biotherapeutics Stock Is Surging: Here's Why
IOVA
-

Benzinga - Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum.

What Happened: According to a new regulatory filing, Rothbaum purchased 10 million shares of Iovance stock at an average price of $6.50 per share at the end of last week. The new buy brings his total position to more than 18 million shares.

Rothbaum's purchase comes just days after several other company directors and executives picked up shares of Iovance stock at prices ranging from $5.98 to $6.31 per share.

Iovance is a clinical-stage biopharmaceutical company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to use a patient's immune system to eliminate cancer cells.

IOVA Price Action: Iovance has a 52-week high of $20.60 and a. 52-week low of $5.42.

The stock was up 22.7% at $8.39 at time of publication, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.